Details

Autor(en) / Beteiligte

• Shinagare, Atul B
• Barysauskas, Constance M
• Braschi-Amirfarzan, Marta
• O'Neill, Ailbhe C
• Catalano, Paul J
• George, Suzanne
• Ramaiya, Nikhil H

Titel

Comparison of Performance of Various Tumor Response Criteria in Assessment of Sunitinib Activity in Advanced Gastrointestinal Stromal Tumors

Ist Teil von

• Clinical imaging, 2016-09, Vol.40 (5), p.880-884

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Purpose To compare the performance of various tumor response criteria (TRC) in the assessment of patients with advanced GIST treated with sunitinib after failure of imatinib. Methods Sixty-two participants with advanced GIST in two clinical trials received oral sunitinib after prior failure of imatinib (median duration 24 weeks; IQR 14–56) and were followed with contrast-enhanced CT at baseline and thereafter at median intervals of 6 weeks (IRQ 6–9). Tumor response was prospectively determined using RECIST1.0, and retrospectively reassessed for comparison using RECIST1.1, Choi, and modified Choi (mChoi) criteria using the original target lesions. For mChoi criteria, PD was defined as 20% increase in sum of longest dimension, similar to RECIST1.1. Clinical benefit rate (CBR; CR, PR or SD ≥ 12 weeks) and progression-free survival (PFS) were compared between various TRCs using kappa statistics. Results While PR as the best response was more frequent by Choi and mChoi criteria (50% each) than RECIST1.1 (15%) and RECIST1.0 (13%), CBR was similar between various TRCs (overall CBR 60–77%, 77–94% agreement between all TRC pairs). Time to best response was shorter for Choi and mChoi criteria (median 11 weeks each) compared to RECIST1.1 and RECIST1.0 (median 25 and 24 weeks, respectively). PFS was similar for RECIST1.1, RECIST1.0 and mChoi (median 35 weeks each), and shortest for Choi criteria (median 23 weeks). Conclusions CBR was similar among the various TRC, although Choi criteria led to earlier determination of disease progression. Therefore, RECIST 1.1 and modified Choi criteria may be preferred for response assessment in patients with advanced GIST.